Mr. Speaker, basically a lot of what could happen could actually happen within the bureaucracy, if we talk to people who know the issue within the government.
These timely reviews of drug submissions are very important, but the fact is that we are lagging behind the rest of the industrialized world, notably the United States and European countries. I am suggesting that we follow the same model that is followed in the European Union. It is not new and it is not innovative. It is basically the bill that I have written. We took a hard look at the process in Europe versus the process here in Canada. We are suggesting that without too much money and without a lot of time we can actually change and improve it. When we do that I think it will be good not only for consumers but for the companies involved as well, and certainly for our health care system.